Revotar Biopharmaceuticals completes first closing of the Company's additional private equity financing

Hennigsdorf, (PresseBox) - Revotar Biopharmaceuticals AG announced today a successful first closing of the actual € 10-15 million private equity financing round, raising € 2,88 million. Millhouse Private Equity Trust, Sydney led the investment, with participation from bmp AG, MVC Unternehmensbeteiligungsgesellschaft mbH and Deutsche Life Science GmbH, all located in Berlin, Germany.

The proceeds of the financing will enable the Company to further pursue the clinical development of the company’s lead product Bimosiamose as well as building up on Revotar’s strong and innovative clinical development pipeline.

Revotar Biopharmaceuticals AG aims to complete the actual financing round before end of this year. Revotar is in promising negotiations with leading Biotech investors from Europe, as well as from the United States.

Revotar Biopharmaceuticals AG

Revotar entwickelt innovative Medikamente zur Behandlung von entzündlichen Erkrankungen wie z. B. Psoriasis, chronisch-obstruktive Lungenerkrankung (COPD) und akutes Lungenversagen (ALI). Der am weitesten fortgeschrittene Medikamentenkandidat Bimosiamose ist bereits in mehreren Phase I und Phase IIa Studien in den Indikationen Asthma, COPD und Psoriasis an fast 200 Freiwilligen und Patienten getestet worden und hat sich dabei als sicher und wirksam erwiesen. Im Sommer 2006 hat Revotar die Unterzeichnung einer Vereinbarung zur Zusammenarbeit mit einem US-amerikanischen Pharmaunternehmen bekannt gegeben, die die Entwicklung der Bimosiamose in einem größeren Indikationsgebiet betrifft.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.